PF-Atlas › Weekly Digest › Week 46, 2026

A New Real-World Nerandomilast Study Opens, Lung Scarring Cell Biology Gets Clearer, and Our Own AI Solver Tests 20 Drug Cocktails

November 2 to 9, 2026 · Active week

Get IPF progress updates by email

This is not a newsletter. It is the real movement in the fight against idiopathic pulmonary fibrosis. New trials opening, new treatments being tested, where the best options stand now, in plain language, once a week. If you or someone you love is living with IPF, this is the progress you want to follow. Confirm your address to start. Unsubscribe anytime.

We email a confirmation link first, so it is really you. No spam, ever.

The week in plain words

This week one new real-world study opened to test nerandomilast, the drug the FDA approved in October 2025 that slows IPF but does not reverse any existing scarring. Twelve new research papers appeared, with the most interesting one mapping out a specific cell type that seems to drive the formation of destructive tiny air pockets in scarred lungs. Our own PF-Atlas discovery engine ran 20 simulated drug-cocktail experiments and produced five speculative new molecule ideas, all clearly computer-generated hypotheses and not treatments anyone can use yet.

Where things stand now

IPF still has no cure and no treatment that reverses scarring. Two drugs, nintedanib and pirfenidone, have been approved for years and slow the disease in many patients. Nerandomilast (brand name Jascayd) joined them after FDA approval in October 2025, also slowing progression but not healing damaged tissue. Inhaled treprostinil is in late-stage trials with an FDA filing expected in 2026. Admilparant is in a large Phase III trial called ALOFT-IPF. Rentosertib has shown early promise in human trials but is not proven yet. Everything else, including cell therapies and gene delivery, is experimental and years away from patients at best.

The best option right now

For someone diagnosed with IPF today, the honestly framed best options are the three clinically approved or near-approved anti-fibrotic medicines. Nerandomilast, nintedanib, and pirfenidone each slow the rate at which lung function declines. None of them undo scarring that already exists, none guarantee the disease stops, and which one fits a particular patient depends on their other health conditions and their doctor's judgment. Admilparant and inhaled treprostinil look promising but are not yet approved. Everything beyond those is investigational and should not be treated as an available option.

How close are we to regeneration

Regenerating scar tissue back into healthy lung is a research goal, not something medicine can do today. The most advanced experimental ideas in this space are uPAR-CAR-T therapy, which uses engineered immune cells to clear the aged, stuck cells thought to prevent healing, and a combination concept pairing senolytics (drugs that clear those same stuck cells) with a molecule called RSPO3 that may help surviving lung stem cells regrow. Both are preclinical, meaning they have not been tested in people with IPF yet. True lung regeneration, if it ever becomes possible, is likely many years away.

Study of the week

The standout paper this week, published in JCI Insight by Toigo, Garakani, Brumwell, and colleagues, looked closely at a specific cell type found in scarred IPF lungs. These cells, called MMP1-high basal cells, appear to come from alveolar type II cells, which are normally the stem cells that maintain the tiny air sacs where oxygen enters the blood. The paper describes how these converted cells seem to actively drive the formation of destructive microcysts, tiny collapsing pockets that make the lung architecture fall apart. This matters because it points to a very specific biological step in the scarring process, one that future drugs could potentially target. It is basic science, not a treatment, but it sharpens the map of what is going wrong inside an IPF lung.

What changed since last week

One new trial opened this week. The real-world study NCT07919015 is now recruiting patients to track how nerandomilast performs in everyday clinical settings outside of a controlled trial, which will add important data about how the drug behaves across a broad range of real patients. No existing trials changed status this week.

Our own search for a cure this week

Every day, PF-Atlas runs its own discovery engine, a genetic-algorithm solver combined with an AI literature scan. To be completely transparent, this is our own software, not findings from outside researchers. The solver does not test drugs in a lab or in patients. Instead it simulates combinations of already-known drugs, including medicines originally developed for completely different diseases, and scores them on a computer model of IPF biology to find pairings worth investigating further. The output is computer-generated hypotheses only, never clinical evidence and never treatments. This week the solver completed 20 combination simulations. It generated five speculative new molecule concepts: an EMP2-AGER bispecific mRNA nanoparticle designed for inhalation, an inhaled neuregulin-1 beta 1 bispecific agonist targeting ErbB4, an oncostatin M fusion protein also designed for inhalation, a Yoda1-AGER mechanotransduction bispecific, and an AGER-NKX2.1 bispecific transcriptional coactivator delivered by inhaled lipid nanoparticle. The solver also added a new candidate class called ECM-Targeted Aberrant Epithelial Repair Modulator to its testing pool. The highest-scoring simulated cocktail this week combined five components: a WNT pathway activator (RSPO3), an ECM remodeling inhibitor, a HOPX activator, a curcumin-based TLR4 and NLRP3 modulator, and a miR-34a inhibitor. The model scored this combination at 99 on its internal FVC-preservation scale. That number is a simulation output from our own model, not a clinical result, and it should be read as a direction for future laboratory investigation, not as evidence that this cocktail works in people. Zero cross-disease drug borrowing candidates and zero additional hypotheses were logged this week outside the solver runs.

Inside the PF-Atlas lab

Strongest simulated combination so far
WNT/RSPO3 agonist + ECM remodeling inhibitor + HOPX activator + Curcumin (TLR4/NLRP3) + miR-34a inhibitor
In our 24-month computer simulation this cocktail of already-known drugs moved lung function (FVC) toward about 99%. A model result and a research hypothesis, not a treatment.
New candidate ideas the solver found
  • EMP2-AGER Bispecific mRNA Nanoparticle (Inhaled)
  • Inhaled Neuregulin-1β1 EGF-Domain / ErbB4 Bispecific Agonist (NRG1β1-ErbB4-Fc)
  • Oncostatin M, Fc Fusion Protein (Inhaled)
  • Yoda1-AGER mRNA Mechanotransduction Bispecific (Inhaled)
  • AGER-NKX2 to 1 Bispecific Transcriptional Coactivator mRNA (inhaled lipid nanoparticle)

Everything here is PF-Atlas computer model output, a hypothesis to guide researchers. It is not clinical evidence and not a treatment anyone can take.

Print this to show your pulmonologist →

Sources this week

New / updated trials
New studies
  • Pathological regulatory roles of lysine acylation modifications in idiopathic pulmonary fibrosis (Review). · Molecular medicine reports 2026 PMID 42960441 on PubMed ↗
  • Jinshui Huanxian Formula Combined with Exercise Rehabilitation Improves Skeletal Muscle Mitochondrial Damage in Treatment of Pulmonary Fibrosis by AMPK/mTOR/HIF-1 Pathway. · Chinese journal of integrative medicine 2026 PMID 42995304 on PubMed ↗
  • Weight Loss, FVC Decline, and Composite Physiologic Index as Complementary Prognostic Indicators in Idiopathic Pulmonary Fibrosis over the Disease Course: Time-Updated and Landmark Analysis. · Archivos de bronconeumologia 2026 PMID 42995110 on PubMed ↗
  • Alveolar Type II Cell-derived MMP1high basal cells promote destructive microcysts in idiopathic pulmonary fibrosis. · JCI insight 2026 PMID 42986692 on PubMed ↗
  • [Unfavorable prognosis of pathogenic variants in the telomerase complex in cases of familial pulmonary fibrosis]. · Revue des maladies respiratoires 2026 PMID 42982616 on PubMed ↗
  • Macrophage-targeted GAS6 siRNA delivery by a multifunctional mannan-peptide nanocarrier attenuates pulmonary fibrosis progression. · Journal of controlled release : official journal of the Controlled Release Society 2026 PMID 42982138 on PubMed ↗
  • Serum decoy receptor 3 is a possible prognostic biomarker in acute exacerbation of idiopathic interstitial pneumonia. · Respiratory investigation 2026 PMID 42976680 on PubMed ↗
  • Exogenous tryptophan aggravates experimental lung fibrosis through activation of AKT-mTORC1 pathway. · PloS one 2026 PMID 42976151 on PubMed ↗
  • Deep learning-based quantification of CT changes after 1 year of pirfenidone treatment as a prognostic marker in idiopathic pulmonary fibrosis. · Insights into imaging 2026 PMID 42975762 on PubMed ↗
  • Reply: Comparative Clinical Outcomes of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis: A Five-Year Real-Life Study. · Thoracic research and practice 2026 PMID 42902608 on PubMed ↗
  • Lifetime Endogenous Estrogen Exposure Predicts Idiopathic Pulmonary Fibrosis Risk in Postmenopausal Women Based on a Nationwide Population Study. · Journal of Korean medical science 2026 PMID 42978134 on PubMed ↗
  • 6-min walk test reveals early physiological impairment in fibrotic interstitial lung diseases. · ERJ open research 2026 PMID 42974372 on PubMed ↗
  • Progressive pulmonary fibrosis in fibrotic interstitial lung disease: a Danish cohort study. · ERJ open research 2026 PMID 42974034 on PubMed ↗
  • A plain language review of the TETON-1 and TETON-2 studies: inhaled treprostinil (Tyvaso) in idiopathic pulmonary fibrosis. · Expert review of respiratory medicine 2026 PMID 42972641 on PubMed ↗
  • [The role of immune checkpoints in idiopathic pulmonary fibrosis: An emerging therapeutic paradigm]. · Revue des maladies respiratoires 2026 PMID 42971859 on PubMed ↗
  • Effectiveness of home-based pulmonary rehabilitation in patients with interstitial lung disease: a systematic review and meta-analysis. · BMJ open respiratory research 2026 PMID 42971730 on PubMed ↗
  • Integrative network toxicology and machine learning reveal the potential role of 5-hydroxymethylfurfural in exacerbating pulmonary fibrosis. · PloS one 2026 PMID 42970606 on PubMed ↗
  • Discovering Biomarkers for Idiopathic Pulmonary Fibrosis by Correlating Serum Extracellular Vesicle Proteins With Clinical Data. · Proteomics. Clinical applications 2026 PMID 42983973 on PubMed ↗
  • Combined Pulmonary Fibrosis and Emphysema: Current Status and Future Perspective. · The clinical respiratory journal 2026 PMID 42977711 on PubMed ↗
  • Treprostinil: Mechanism of Action, Clinical, and Translational Science. · Clinical and translational science 2026 PMID 42969503 on PubMed ↗
Get IPF progress updates by email

This is not a newsletter. It is the real movement in the fight against idiopathic pulmonary fibrosis. New trials opening, new treatments being tested, where the best options stand now, in plain language, once a week. If you or someone you love is living with IPF, this is the progress you want to follow. Confirm your address to start. Unsubscribe anytime.

We email a confirmation link first, so it is really you. No spam, ever.
Medical disclaimer. This digest summarizes public clinical-trial and research data in plain language for information only. It is not medical advice, a treatment recommendation, or a promise of any outcome. Evidence changes; treatments described as investigational are not proven cures. Always verify with ClinicalTrials.gov, PubMed and a qualified pulmonologist before any decision.